Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis xltg11 + lactobacillus plantarum ccfm8661

Development stage: Preclinical
Lead developer: Heilongjiang University of Chinese Medicine
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is a combination of two probiotic strains, Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM8661, intended for use as a live biotherapeutic product or dietary supplement to support gut health and modulate the intestinal microbiota. Bifidobacterium animalis subsp. lactis XLTG11 has been shown to promote recovery of intestinal flora and mucosal barrier function, reduce intestinal permeability, increase short-chain fatty acid production, and modulate inflammatory responses[1][5]. Lactobacillus plantarum CCFM8661 has demonstrated protective effects against oxidative stress in the brain and colon, improves behavioral performance in mice exposed to toxins such as benzopyrene (B[a]P), increases gut microbiota diversity, enhances intestinal barrier integrity, and boosts SCFA production[6][8]. The combination may offer synergistic benefits for gastrointestinal health by restoring microbial balance and supporting immune function.

Other names: 动物双歧杆菌乳亚种XLTG11 + 植物乳酸杆菌CCFM8661Bifidobacterium animalis subsp. lactis XLTG11 + Lactiplantibacillus plantarum CCFM8661

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis xltg11 + lactobacillus plantarum ccfm8661.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis xltg11 + lactobacillus plantarum ccfm8661.

Explore the full profile